Cash and cash equivalents

Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform

Friday, August 7, 2020 - 12:30pm

Revenue for the second quarter of 2020 increased 55% to $1.7 million compared to $1.1 million for the second quarter of 2019.

Key Points: 
  • Revenue for the second quarter of 2020 increased 55% to $1.7 million compared to $1.1 million for the second quarter of 2019.
  • We have also maintained a solid balance sheet with over $97.5 million of cash and cash equivalents as of June 30, 2020.
  • Our true progress can be seen in the advancement of our POCare Therapeutics pipeline, including immuno-oncology, metabolic, and anti-viral therapies.
  • Our POCare Network also continues to grow via new partnerships with leading hospitals and research institutes around the world.

Jounce Therapeutics Reports Second Quarter 2020 Financial Results

Friday, August 7, 2020 - 11:30am

- Ended the quarter with $127.2 million in cash, cash equivalents and investments -

Key Points: 
  • - Ended the quarter with $127.2 million in cash, cash equivalents and investments -
    CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the second quarter ended June30, 2020 and provided a corporate update.
  • Second Quarter 2020 Financial Results:
    Cash position: As of June30, 2020, cash, cash equivalents and investments were $127.2 million, compared to $170.4 million as of December31, 2019.
  • License and collaboration revenue: Jounce did not recognize any revenue in the second quarter of 2020.
  • Net loss: Net loss was $28.0 million for the second quarter of 2020, resulting in basic and diluted net loss per share of $0.82.

Ero Copper Reports Second Quarter Results

Thursday, August 6, 2020 - 10:12pm

(all amounts in US dollars, unless otherwise noted)

Key Points: 
  • (all amounts in US dollars, unless otherwise noted)
    VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Ero Copper Corp. (the Company) (TSX: ERO) today is pleased to announce its financial results for the three and six months ended June 30, 2020.
  • While preliminary results are encouraging, additional detail on these ongoing exploration programs continues to be expected during the second half of the year.
  • The Company expects the HIG Mill to be fully operational during the third quarter with a resulting improvement in copper recoveries expected during the second half of 2020.
  • Ended the second quarter with strong liquidity position of approximately $51.6 million in cash and cash equivalents.

Merus Announces Financial Results for the Second Quarter and Provides Business Update

Thursday, August 6, 2020 - 9:07pm

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and TriclonicsTM), today announced financial results for the second quarter that ended June30, 2020, and provided a business update.

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and TriclonicsTM), today announced financial results for the second quarter that ended June30, 2020, and provided a business update.
  • We are pleased to report several updates and progress with our business this quarter, said Bill Lundberg, M.D., President, Chief Executive Officer and Principal Financial Officer of Merus.
  • We look forward to providing a substantive clinical update on zenocutuzumab (Zeno) for neuregulin 1 (NRG1) fusion cancers by year end.
  • The Company ended the second quarter with cash, cash equivalents and marketable securities of $197.4 million compared to $241.8 million at December 31, 2019.

NextCure Reports Second Quarter 2020 Financial Results

Thursday, August 6, 2020 - 9:03pm

BELTSVILLE, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2020 financial results and provided a business update.

Key Points: 
  • BELTSVILLE, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2020 financial results and provided a business update.
  • Financial Results for Quarter Ended June 30, 2020
    Cash, cash equivalents and marketable securities as of June 30, 2020 were $309.3 million, compared to $334.6 million as of December 31, 2019.
  • Research and development expenses were $11.1 million for the quarter ended June 30, 2020, as compared to $7.6 million for the quarter ended June 30, 2019.
  • There was no revenue recognized in the quarter ended June 30, 2020 as compared to $1.4 million in the quarter ended June 30, 2019.

Editas Medicine Announces Second Quarter 2020 Results and Update

Thursday, August 6, 2020 - 9:05pm

Cash, cash equivalents, and marketable securities of $599 million as of June 30, 2020

Key Points: 
  • Cash, cash equivalents, and marketable securities of $599 million as of June 30, 2020
    CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2020.
  • The Company remains on track to file an investigational new drug application (IND) for EDIT-301 by the end of 2020.
  • Editas Medicine plans to present preclinical data on EDIT-201 at a scientific conference in the second half of 2020.
  • ET to provide and discuss a corporate update and financial results for the second quarter of 2020.

Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update

Thursday, August 6, 2020 - 9:05pm

For the second quarter and first six months of 2020, Prothena reported a net loss of $26.3 million and $49.9 million, respectively, as compared to a net loss of $15.8 million and $36.7 million for the second quarter and first six months of 2019, respectively.

Key Points: 
  • For the second quarter and first six months of 2020, Prothena reported a net loss of $26.3 million and $49.9 million, respectively, as compared to a net loss of $15.8 million and $36.7 million for the second quarter and first six months of 2019, respectively.
  • Research and development (R&D) expenses totaled $17.3 million and $32.5million for the second quarter and first six months of 2020, respectively, as compared to $9.6 million and $22.9million for the second quarter and first six months of 2019, respectively.
  • Total non-cash share-based compensation expense was $5.7 million and $11.2 million for the second quarter and first six months of 2020, respectively, as compared to $6.3 million and $12.5 million for the second quarter and first six months of 2019, respectively.
  • As of June30, 2020, Prothena had $336.6 million in cash, cash equivalents and restricted cash and no debt.

Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates

Thursday, August 6, 2020 - 9:10pm

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the second quarter ended June 30, 2020 and provided corporate updates.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the second quarter ended June 30, 2020 and provided corporate updates.
  • We are excited for this momentum to continue building in the second half of 2020 as we advance our mission to serve patients.
  • Financial Results for the Second Quarter 2020 and Six Months Ended June 30, 2020
    Cash, cash equivalents and investments in marketable securities were $462.5 million as of June 30, 2020, compared to $188.3 million at December 31, 2019.
  • Risks and uncertainties facing Arcus are described more fully in Arcuss quarterly report on Form 10-Q for the quarter ended June 30, 2020 filed on August 6, 2020 with the SEC.

Five Prime Therapeutics Reports Second Quarter 2020 Results

Thursday, August 6, 2020 - 9:05pm

Summary of Second Quarter 2020 Financial Results and Cash Guidance:

Key Points: 
  • Summary of Second Quarter 2020 Financial Results and Cash Guidance:
    Cash Position: Cash, cash equivalents and marketable securities totaled $128.6 million as of June 30, 2020 compared to $157.9 million as of December 31, 2019.
  • Revenue: Collaboration and license revenue for the second quarter of 2020 was $3.4 million, which was essentially on par with second quarter 2019 revenue of $3.3 million.
  • R&D Expenses: Research and development expenses for the second quarter of 2020 decreased by $16.9 million, or 57%, to $12.6 million from $29.4 million for second quarter of 2019.
  • G&A Expenses: General and administrative expenses for the second quarter of 2020 decreased by $1.7 million, or 17%, to $8.0 million from $9.7 million for the second quarter of 2019.

Stealth BioTherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights

Thursday, August 6, 2020 - 12:30pm

BOSTON, Aug. 6, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.

Key Points: 
  • BOSTON, Aug. 6, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.
  • Financial Results for the Three Months Ended June 30, 2020
    Cash Position:Cash and cash equivalents were $31.8million at June 30, 2020, compared to $50.8million at December31, 2019.
  • Management will host a conference call today at 8:30 am ET to discuss the financial results and provide a general business update.
  • Statements that are not historical facts, including statements about Stealth BioTherapeutics' beliefs, plans and expectations, are forward-looking statements.